RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bionano Genomics Stock

Bionano Genomics Market capitalization 2024

Bionano Genomics Market capitalization

13.85 M USD

Ticker

BNGO

ISIN

US09075F1075

WKN

A2JRLZ

In 2024, Bionano Genomics's market cap stood at 13.85 M USD, a -85.47% increase from the 95.28 M USD market cap in the previous year.

The Bionano Genomics Market capitalization history

YEARMarket Capitalization (undefined USD)
20230.24
20220.6
20211.81
20200.07
20190.04
20180.07
2017-
2016-

Bionano Genomics Aktienanalyse

What does Bionano Genomics do?

Bionano Genomics Inc. is a biotechnology company specializing in the development of DNA analysis systems. The company is headquartered in California and was founded in 2003. History: The company was originally established as a research group at the University of California, San Diego. Over the years, the group has evolved into a leading company in DNA analysis and genome analysis. Business model: Bionano Genomics Inc. has a business model based on the analysis and processing of DNA sequences. The company offers its products and services in three different business areas: genomic research, clinical research, and diagnostics. Products: The company has introduced a range of products that help revolutionize genomics. One of Bionano Genomics' most important products is the Saphyr system. This system uses optical DNA mapping technology to make DNA sorting and mapping more efficient. The Saphyr system can contribute to improving and accelerating genomic research in various industries. Another product of the company is the COVID-19 assay. This assay is used in the detection of COVID-19. It is used in the laboratory and is fast and accurate. Divisions: Bionano Genomics offers its products and services in three different business areas: genomic research, clinical research, and diagnostics. Genomic research: Bionano Genomics works closely with research institutes and companies to perform DNA analysis. The Saphyr system is used to analyze DNA samples and conduct genome studies. With this technology, it has become possible to visualize large genomic regions to gain insights into complex genomic changes and rearrangements, such as those related to cancer. Clinical research: The company works closely with clinicians to conduct clinical studies and diagnose diseases. The Saphyr system can help in the investigation of structural DNA variants associated with specific diseases such as autism, schizophrenia, and epilepsy. Diagnostics: Bionano Genomics also offers services for the diagnosis of genetic disorders. The company provides tests that examine genetic markers and indicators to make an accurate diagnosis. The company also offers genetic counseling services to help families affected by genetic diseases. Overall, Bionano Genomics has the potential to change the way we study, diagnose, and treat genetic diseases. The company has already formed partnerships with several industry leaders and research institutions to advance its research. Bionano Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Bionano Genomics's Market Capitalization

Bionano Genomics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Bionano Genomics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Bionano Genomics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Bionano Genomics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Bionano Genomics stock

What is the current Bionano Genomics market capitalization?

The current market capitalization of Bionano Genomics is 13.85 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Bionano Genomics.

How has the market capitalization of Bionano Genomics developed in recent years?

The market capitalization of Bionano Genomics has increased/decreased by -85.47% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Bionano Genomics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Bionano Genomics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Bionano Genomics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Bionano Genomics pay?

Over the past 12 months, Bionano Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bionano Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bionano Genomics?

The current dividend yield of Bionano Genomics is .

When does Bionano Genomics pay dividends?

Bionano Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bionano Genomics?

Bionano Genomics paid dividends every year for the past 0 years.

What is the dividend of Bionano Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bionano Genomics located?

Bionano Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bionano Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bionano Genomics from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Bionano Genomics pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Bionano Genomics in the year 2023?

In the year 2023, Bionano Genomics distributed 0 USD as dividends.

In which currency does Bionano Genomics pay out the dividend?

The dividends of Bionano Genomics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bionano Genomics

Our stock analysis for Bionano Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionano Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.